Public Companies
Mind Cure Health to Acquire South American Utility Company
Mind Cure will change its name to LNG Energy Group Inc.
The post Mind Cure Health to Acquire South American Utility Company appeared first on Green Market…
Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF), a Canadian psychedelics clinical research company that announced in March that it was shutting down, said on Tuesday that it has signed a binding letter of intent to acquire Latin American utility company LNG Energy Group Inc.
Terms of the deal were not disclosed, though a release will provide details by Dec. 31, when the two come to a definitive agreement. The deal is expected to close in the first quarter of 2023.
The board and company officers will reshuffle among existing members whenever the deal goes through, the company said.
In a statement, Mind Cure said it plans to consolidate existing share capital on a 2.4-for-1 basis and changing its name to “LNG Energy Group Inc.”
The company also said that it would draw out private placements and debt financing to allow LNG to acquire a company that “holds operating oil and gas field properties in South America.”
All outstanding securities of LNG will be exchanged for identical securities of the new entity on a post-consolidation one-for-one basis. The deal will be reviewed by the Canadian Securities Exchange before it can close.
LNG Energy plans on securing a private placement worth between $15 million-$30 million, as well drawing bank debt financing of between $65 million-$85 million.
The company also plans to utilize a nonbrokered private placement of Mind Cure shares at a price of $0.05 per share and a purchase warrant with an exercise price of at least $0.07 per warrant for total proceeds of up to $4 million worth of Mind Cure shares.
The company plans on using the private placements and the debt financing to fund working capital and acquire certain natural gas assets located in Latin America.
The post Mind Cure Health to Acquire South American Utility Company appeared first on Green Market Report.
psychedelics financing private placement shares fund cse deal capital mind cure health mind cure research-
Psychedelics7 days ago
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
-
Psilocybin6 days ago
Are Shrooms Legal in Oregon: Full Guide
-
Law & Regulation1 week ago
Numinus reports declining revenue as the company restructures
-
Law & Regulation7 days ago
Going concern warnings cloud Xtacy Therapeutics’ shrunk losses
-
Psychedelics7 days ago
Optimi Health Achieves Milestone: Completes In-House Production of MDMA Active Pharmaceutical Ingredient (API)
-
Psychedelics7 days ago
Psyence Group’s NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
-
Psychedelics6 days ago
Atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
-
Law & Regulation5 days ago
Clearmind signs agreement with Hebrew University for psychedelic compound rights